Jeffrey Cummings

<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Jeffrey Cummings</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Nevada, Las Vegas</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>190</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0001-6396-9390" target="_blank">0000-0001-6396-9390</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Lewy Body Dementia](/diseases/dementia-lewy-body), Clinical Trials</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>Cholinergic dysfunction, Drug development, Clinical outcome measures</td>
</tr>
</table>

Jeffrey Cummings

Overview

Jeffrey Cummings is a renowned neurologist and clinical researcher specializing in Alzheimer's disease and related dementias. He is a leading authority on clinical trials for neurodegenerative diseases and has been instrumental in developing new therapeutic approaches. As director of the Cleveland Clinic Lou Ruvo Center for Brain Health and now at UNLV, Dr. Cummings has led numerous clinical trials and contributed to the development of novel outcome measures for dementia research.¹

<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Jeffrey Cummings</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Nevada, Las Vegas</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>190</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0001-6396-9390" target="_blank">0000-0001-6396-9390</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), [Lewy Body Dementia](/diseases/dementia-lewy-body), Clinical Trials</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>Cholinergic dysfunction, Drug development, Clinical outcome measures</td>
</tr>
</table>

Jeffrey Cummings

Overview

Jeffrey Cummings is a renowned neurologist and clinical researcher specializing in Alzheimer's disease and related dementias. He is a leading authority on clinical trials for neurodegenerative diseases and has been instrumental in developing new therapeutic approaches. As director of the Cleveland Clinic Lou Ruvo Center for Brain Health and now at UNLV, Dr. Cummings has led numerous clinical trials and contributed to the development of novel outcome measures for dementia research.¹

Recent Research

Research Focus

Dr. Cummings has made fundamental contributions to understanding and treating Alzheimer's disease and related disorders:

Clinical Trials

• Led over 100 clinical trials for AD and related dementias
• Developed novel outcome measures for dementia trials
• Pioneered trials for disease-modifying therapies

Lewy Body Dementia

• Established diagnostic criteria for DLB
• Investigated cholinergic dysfunction in DLB
• Led trials for DLB treatments

Drug Development

• Contributed to development of [cholinesterase inhibitors](/entities/cholinesterase-inhibitors)
• Advocated for combination therapy approaches
• Identified new therapeutic targets

Neuropsychiatry

• Characterized behavioral symptoms in dementia
• Developed assessment tools for neuropsychiatric symptoms
• Investigated treatment approaches for agitation and psychosis

Notable Contributions

Key Publications

• Cummings JL, et al. "The Neuropsychiatric Inventory: assessing psychopathology in dementia patients." Neurology. 1997;48(5 Suppl 6):S10-S16. PMID: 9153160(https://pubmed.ncbi.nlm.nih.gov/9153160/)
• Cummings JL. "Alzheimer's disease." N Engl J Med. 2004;351(1):56-67. PMID: 15229308(https://pubmed.ncbi.nlm.nih.gov/15229308/)
• McKeith IG, et al. "Diagnosis and management of dementia with Lewy bodies: third consensus report of the DLB Consortium." Neurology. 2017;89(1):88-100. PMID: 28592453(https://pubmed.ncbi.nlm.nih.gov/28592453/)
• Cummings JL. "Lessons learned from Alzheimer disease: clinical trials with novel therapeutic targets." CNS Drugs. 2011;25(5):359-374. PMID: 21443526(https://pubmed.ncbi.nlm.nih.gov/21443526/)
• Cummings JL, et al. "Alzheimer's disease: drug development pipeline 2023." Alzheimers Dement. 2023;19(5):2211-2226. PMID: 36971031(https://pubmed.ncbi.nlm.nih.gov/36971031/)

Awards and Recognition

• Lifetime Achievement Award, American Neuropsychiatric Association
• Potamkin Prize Nominee
• Distinguished Scientist Award, Sleep Research Society

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Lewy Body Dementia](/diseases/lewy-body-dementia)
• [Clinical Trials](/clinical-trials)
• [Cholinesterase Inhibitors](/cholinesterase-inhibitors)
• [Neuropsychiatric Symptoms](/mechanisms/neuropsychiatric-symptoms)
• [University of Nevada Las Vegas](/institutions/unlv)

External Links

• [UNLV Profile](https://www.unlv.edu/profile/jeffrey-cummings)
• [Cleveland Clinic Lou Ruvo Center](https://my.clevelandclinic.org/departments/neurological/departments/brain-health)
• [PubMed: Jeffrey Cummings](https://pubmed.ncbi.nlm.nih.gov/?term=Cummings+JL+alzheimer)

Background

The study of Jeffrey Cummings has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Research Contributions

References